Navigation Links
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Date:12/11/2011

p>Dr. Meyer will present this study in an oral presentation on Monday, December 12, at 3:00 p.m. PST at the San Diego Convention Center in Ballroom 20A.

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study [Abstract 269]

The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy.

NHL survival rates have increased dramatically in the last several decades because of such proven and effective targeted therapies as rituximab that aim directly at the key molecular features of the disease. Despite advances in NHL treatment, hematologists continue to be challenged by drug resistance and disease relapses among their patients. Obinutuzumab, also known as GA101, is a new investigational therapy and the first type II bio-engineered monoclonal antibody specifically targeting CD20 (a prominent lymphoma biomarker) to be studied for use in NHL. Early research with GA101 has shown potential anti-lymphoma activity, but no studies have compared the results against current clinical options directly.

To compare the efficacy and safety of GA101 versus rituximab in patients with relapsed NHL, an international Phase II clinical trial was undertaken measuring overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety outcomes among patients on both treatments. A total of 175 patients were randomized to receive four weekly injections of either GA101 or rituximab with response to treatment assessed between 28 and 42 days after the last dose. Those patients who responded to treatment received ongoing doses of GA101 or rituximab every t
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Established and Emerging Biotech Clusters
2. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
3. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications
4. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot
5. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
6. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
7. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
8. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors
9. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
10. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers
11. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Dose-Escalation Study Presented at , American Association for ... FRANCISCO, Calif. and DENVER, April 21 Poniard ... biopharmaceutical company focused on oncology, today announced the ... dose-escalation study of picoplatin in patients with metastatic ...
... In Vivo Data Show AEZS-126 as Promising Oral Compound ... 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: ... on endocrine therapy and oncology, today presented two posters ... the PI3K/ Akt pathway in human tumors. The posters ...
... 21 GenVault, a leading provider of room-temperature ... release today of GenConnect 3.2, the newest version ... Highlights of the release include a strategic licensing ... into third-party informatics offerings, as well as a ...
Cached Biology Technology:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 5AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 2AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting 3GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 2GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2 3
(Date:4/18/2014)... the story of how barnyard chickens came to be, finds ... Proceedings of the National Academy of Sciences . , ... years ago in Europe, researchers report that just a few ... from the chickens we know today. , The results suggest ... chickens -- such as their yellowish skin -- only became ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological havoc, ... global scales. But new research from Brown University shows ... life at the time of an impact. , A ... found fragments of leaves and preserved organic compounds lodged ... Argentina. The material could provide a snapshot of environmental ...
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... In the latest version of the hide-and-seek game between pathogens ... virus appears to cloak itself with a recently discovered gene ... , The report by Howard Hughes Medical Institute (HHMI) researchers ... of Nature may be the first to show how a ...
... Information with Figures (pdf download) , ... law postulated by Ernst Abbe in 1873 for ... and his co-workers have established a new law ... applications range from the imaging of cell interiors ...
... researchers led by the University of Toronto has charted ... in the brain - a discovery that has implications ... stress. , U of T physiology professor Min Zhuo ... National University in South Korea, and Professor Bao-Ming Li ...
Cached Biology News:Virus uses tiny RNA to evade the immune system 2Virus uses tiny RNA to evade the immune system 3New law for resolution allows unprecedented sharpness in fluorescence microscopy 2New law for resolution allows unprecedented sharpness in fluorescence microscopy 3Study charts origins of fear 2
...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: